Chronic hepatitis B: A treatment update

Seminars in Liver Disease

Volumn 33, Issue 2, 2013, Pages 122-129

  Wong, Vincent ^a,b   Chan, Henry ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

cirrhosis; entecavir; hepatocellular carcinoma; peginterferon; tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPOPHOSPHATEMIA; IMMUNOMODULATION; LIVER CELL CARCINOMA; MONOTHERAPY; MYOPATHY; NEPHROTOXICITY; OSTEOLYSIS; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG MONITORING; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84878844939     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1345715     Document Type: Article

References (56)

1. Liaw Y. F., Sung J. J., Chow W. C., et al. Cirrhosis Asian Lamivudine Multicentre Study Group Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med: 2004; 351 15 1521 1531
2. Sung J. J., Tsoi K. K., Wong V. W., Li K. C., Chan H. L. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther: 2008; 28 9 1067 1077
3. Wong G. L., Yiu K. K., Wong V. W., Tsoi K. K., Chan H. L. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther: 2010; 32 9 1059 1068
4. Wong V. W., Wong G. L., Chim A. M., et al. Surrogate end points and long-term outcome in patients with chronic hepatitis B. Clin Gastroenterol Hepatol: 2009; 7 10 1113 1120
5. Wong V. W., Wong G. L., Yan K. K., et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology: 2010; 51 6 1945 1953
6. Zoutendijk R., Reijnders J. G., Zoulim F., et al. for the VIRGIL Surveillance Study Group. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut: 2012
7. Moucari R., Korevaar A., Lada O., et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol: 2009; 50 6 1084 1092
8. Fung J., Lai C. L., Tanaka Y., et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol: 2009; 104 8 1940 1946, quiz 1947
9. Lee H. W., Lee H. J., Hwang J. S., et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology: 2010; 51 2 415 421
10. Liang Y., Jiang J., Su M., et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther: 2011; 34 3 344 352
11. Chen C. J., Yang H. I., Su J., et al. REVEAL-HBV Study Group Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA: 2006; 295 1 65 73 (Pubitemid 43042691)
12. Lok A. S., McMahon B. J. Chronic hepatitis B: update 2009. Hepatology: 2009; 50 3 661 662
13. European Association For The Study Of The Liver EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol: 2012; 57 1 167 185
14. Liaw Y. F., Kao J. H., Piratvisuth T., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int: 2012; 6 3 531 561
15. Janssen H. L., Gerken G., Carreño V., et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology: 1999; 30 1 238 243 (Pubitemid 29300592)
16. Cooksley W. G., Piratvisuth T., Lee S. D., et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat: 2003; 10 4 298 305 (Pubitemid 36801917)
17. Zhao H., Kurbanov F., Wan M. B., et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis: 2007; 44 4 541 548 (Pubitemid 46233256)
18. Lau G. K., Piratvisuth T., Luo K. X., et al. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med: 2005; 352 26 2682 2695 (Pubitemid 41007823)
19. Marcellin P., Lau G. K., Bonino F., et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med: 2004; 351 12 1206 1217 (Pubitemid 39296307)
20. Liaw Y. F., Jia J. D., Chan H. L., et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology: 2011; 54 5 1591 1599
21. Janssen H. L., van Zonneveld M., Senturk H., et al. HBV 99-01 Study Group; Rotterdam Foundation for Liver Research Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet: 2005; 365 9454 123 129 (Pubitemid 40091801)
22. Chan H. L., Leung N. W., Hui A. Y., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med: 2005; 142 4 240 250 (Pubitemid 40216241)
23. Buster E. H., Hansen B. E., Lau G. K., et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology: 2009; 137 6 2002 2009
24. Bonino F., Marcellin P., Lau G. K., et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut: 2007; 56 5 699 705 (Pubitemid 46662938)
25. Sonneveld M. J., Wong V. W., Woltman A. M., et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology: 2012; 142 3 513 520.e1
26. Fried M. W., Piratvisuth T., Lau G. K., et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology: 2008; 47 2 428 434 (Pubitemid 351280710)
27. ter Borg M. J., van Zonneveld M., Zeuzem S., et al. HBV 99-01 Study Group Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology: 2006; 44 3 721 727 (Pubitemid 44433729)
28. Chan H. L., Wong V. W., Wong G. L., Chim A. M., Chan H. Y., Sung J. J. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol: 2008; 6 9 1022 1026
29. Chan H. L., Thompson A., Martinot-Peignoux M., et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol: 2011; 55 5 1121 1131
30. Piratvisuth T., Marcellin P., Popescu M., Kapprell H. P., Rothe V., Lu Z. M. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int: 2011;. [Epub ahead of print]
31. Rijckborst V., Hansen B. E., Ferenci P., et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol: 2012; 56 5 1006 1011
32. Marcellin P., Brunetto M. R., Bonino F., et al. In patients with HBeAg-negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment. Hepatology: 2008;; 48 (4, Suppl): 718A 719A
33. Hui A. Y., Chan H. L., Cheung A. Y., Cooksley G., Sung J. J. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther: 2005; 22 6 519 528 (Pubitemid 41360798)
34. Piccolo P., Lenci I., Demelia L., et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther: 2009; 14 8 1165 1174
35. Sheng J. F., Bai X. F., Wu S. H., et al. A novel combination regimen of peginterferon alfa-2a and entecavir results in sustained post-treatment HBsAg clearance in HBeAg-positive chronic hepatitis B (CHB). Hepatology: 2011; 54 01 1017A
36. Lutgehetmann M., Volzt T., Quaas A., et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther: 2008; 13 1 57 66 (Pubitemid 351541674)
37. Gish R. G., Lau D. T., Schmid P., Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol: 2007; 102 12 2718 2723 (Pubitemid 350179320)
38. Lampertico P., Viganò M., Di Costanzo G. G., et al. PegBeLiver Study Group Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut: 2013; 62 2 290 298
39. Tenney D. J., Rose R. E., Baldick C. J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology: 2009; 49 5 1503 1514
40. Wong G. L., Wong V. W., Chan H. Y., et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther: 2012; 35 11 1326 1335
41. Yuen M. F., Seto W. K., Fung J., Wong D. K., Yuen J. C., Lai C. L. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol: 2011; 106 7 1264 1271
42. Heathcote E. J., Marcellin P., Buti M., et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology: 2011; 140 1 132 143
43. Amini-Bavil-Olyaee S., Herbers U., Sheldon J., Luedde T., Trautwein C., Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology: 2009; 49 4 1158 1165
44. van Bömmel F., Zöllner B., Sarrazin C., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology: 2006; 44 2 318 325 (Pubitemid 44214870)
45. Tan J., Degertekin B., Wong S. N., Husain M., Oberhelman K., Lok A. S. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol: 2008; 48 3 391 398
46. Berg T., Marcellin P., Zoulim F., et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology: 2010; 139 4 1207 1217
47. van Bömmel F., de Man R. A., Wedemeyer H., et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology: 2010; 51 1 73 80
48. Patterson S. J., George J., Strasser S. I., et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut: 2011; 60 2 247 254
49. Izzedine H., Hulot J. S., Launay-Vacher V., et al. Adefovir Dipivoxil International 437 Study Group; Adefovir Dipivoxil International 438 Study Group Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int: 2004; 66 3 1153 1158 (Pubitemid 39121022)
50. Stellbrink H. J., Orkin C., Arribas J. R., et al. ASSERT Study Group Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis: 2010; 51 8 963 972
51. Liaw Y. F., Gane E., Leung N., et al. GLOBE Study Group 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology: 2009; 136 2 486 495
52. Sung J. J., Lai J. Y., Zeuzem S., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol: 2008; 48 5 728 735
53. Lai C. L., Leung N., Teo E. K., et al. Telbivudine Phase II Investigator Group A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology: 2005; 129 2 528 536 (Pubitemid 41096641)
54. Petersen J., Ratziu V., Buti M., et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol: 2012; 56 3 520 526
55. Lok A. S., Trinh H., Carosi G., et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology: 2012; 143 3 619 628, e1
56. Chan H. L., Wong G. L., Chim A. M., Chan H. Y., Chu S. H., Wong V. W. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther: 2011; 16 8 1249 1257